Navigation Links
Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
Date:9/24/2008

Safety and Pharmacokinetic Results in Healthy Volunteers to be Presented at

AASLD

SAN DIEGO, Sept. 24 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today preliminary results of a Phase I clinical trial of ANA598 in healthy volunteers and finalization of the protocol for a Phase Ib trial of ANA598 in patients chronically infected with hepatitis C virus (HCV). In the healthy volunteer study, ANA598 was well tolerated at all doses analyzed to date and no serious adverse events were reported. All doses achieved plasma drug concentrations predicted to display substantial antiviral activity based on preclinical results. The upcoming Phase Ib study of ANA598 in HCV patients will explore three dose levels -- 200 mg, 400 mg, and 800 mg, each taken twice daily (bid). ANA598 is the company's investigational hepatitis C non-nucleoside polymerase inhibitor.

Phase I Study Results

In the Phase I study in healthy volunteers, ANA598 was administered as capsules at single doses starting at 400 mg. At the 2000 mg dose level, it was administered when fasted and also following a meal. In addition, a separate cohort received two 800 mg doses twelve hours apart. ANA598 was well tolerated at all doses analyzed to date and no serious adverse events were reported, although definitive conclusions regarding product safety and tolerability cannot be made until the results of future clinical trials of longer duration in more patients are known. The pharmacokinetic profile demonstrated sustained plasma levels of ANA598 with a half-life of more than 24 hours, consistent with the potential for once-daily or twice-daily oral dosing. All doses achieved plasma drug concentrations predict
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
2. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
5. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
7. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
8. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
9. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
10. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
11. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... --  Sigma-Aldrich Corporation (NASDAQ: SIAL ) a leading ... $50,000 product donation to the Reproducibility Project: Cancer ... from recent high-impact papers in the field of cancer ... research marketplace Science Exchange , the non-profit ... eLife. The goal of the project is ...
(Date:5/6/2015)... LONDON , May 6, 2015 ... HIV maintenance therapy with dolutegravir and rilpivirine ... start of a Phase III clinical trial programme ... (Tivicay®) and rilpivirine (Edurant® [1] ) as maintenance ... III programme comprises two replicate studies evaluating 48 ...
(Date:5/5/2015)... BARCELONA, Spain , May 6, 2015 ... and aspires to lead the European market in the ... Through this alliance ECUPHAR acquires all the assets ... the new organization in the coming weeks. Being both ... not been disclosed.      (Photo: http://photos.prnewswire.com/prnh/20150506/743274 ...
Breaking Medicine Technology:Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 2Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 2ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 4ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 5ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 6ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 7ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 8ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 9ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 10ECUPHAR Enters the Spanish and Southern European Markets Through ESTEVE 2
... SOUTH SAN FRANCISCO, Calif., March 2 Hana,Biosciences ... an Independent Data Monitoring,Committee (IDMC) has completed a ... ongoing pivotal rALLy clinical trial of Marqibo(R) (vincristine,sulfate ... lymphoblastic,leukemia (ALL) in second relapse. The results ...
... (ASX: PXS, Nasdaq: PXSL ) today announced ... the U.S. Food and Drug Administration (FDA) for Aridol, ... to help in the correct diagnosis and assessment of ... was based on a pre-NDA meeting with the FDA ...
Cached Medicine Technology:Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 2Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 3Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 4Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 5Pharmaxis Announces New Drug Application Submission for Aridol(TM) 2Pharmaxis Announces New Drug Application Submission for Aridol(TM) 3
(Date:5/6/2015)... Water NSW (New South ... manage and distribute imagery, LiDAR, and Elevation Data within ... driest continents on earth, and the need to ensure ... erratic seasonal rainfalls has driven the development of several ... manages raw water supplies for NSW, including high quality ...
(Date:5/6/2015)... May 06, 2015 The GUARDaHEART Foundation ... Community Resource Exchange with the mission of providing basic ... families in need on Thursday, April 30th. , ... advanced blood test for the early-detection and diagnosis of ... changing advanced medical testing to homeless individuals and families. ...
(Date:5/6/2015)... Francisco, CA (PRWEB) May 06, 2015 ... accelerator program - today announced the latest lineup of ... Innovation Summit . The invitation-only event, scheduled for May ... of senior care executives, consumer technology leaders, investors and ... discuss emerging trends, cultivate partnerships and discover new products ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Established by ... wellness for the estimated 46 million Americans who suffer ... upon monthly medications to alleviate their symptoms. Medicationdiscountcard.com is ... to save patients money on the costs of these ... are used to treat the pain and inflammation in ...
(Date:5/6/2015)... May 06, 2015 Qualidigm ... Conn., has hired healthcare executive Ann Olson, RN, ... Olson will lead Qualidigm’s growing home healthcare services ... to improve the quality, safety, and cost-effectiveness of ... Qualidigm from Interim HealthCare of North Haven, Inc., ...
Breaking Medicine News(10 mins):Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 3Health News:GUARDaHEART and Starbucks® Collaborate for Impactful Event to Help Homeless Families 2Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 2Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 3Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 4Health News:Medicationdiscountcard.com Provides Access to Drug Coupons for Arthritis Awareness Month 2Health News:Medicationdiscountcard.com Provides Access to Drug Coupons for Arthritis Awareness Month 3Health News:Innovative Healthcare Executive Ann Olson Joins Qualidigm as Principal and Vice President 2Health News:Innovative Healthcare Executive Ann Olson Joins Qualidigm as Principal and Vice President 3
... Niedelman, former deputy associate commissioner for regulatory operations for the ... firm Crowell & Moring LLP as senior consultant ... Group. Niedelman is the firm,s second major hire in recent ... gained Cathy L. Burgess, former associate general counsel for the ...
... Jan. 28 The Savvy Self-Funding,Healthcare Conference and Expo ... discuss creative healthcare options during a June 1-3, 2009,conference ... The conference is unique, as it is designed and ... Karrie Andes, SPHR, Director of Human,Resources, created ...
... while 30% are pre-diabetic, study finds , , WEDNESDAY, Jan. 28 ... diabetes in the United States finds that almost 13 percent ... percent of whom have not been diagnosed. , That,s a ... study, although the percentage of undiagnosed individuals has remained the ...
... in a murder case over 5000 years old. New investigations by ... the chronology of the injuries that Oetzi, the glacier man preserved ... out, for example, that he did in fact only survive the ... a few minutes to a number of hours, but no more ...
... CHICAGO Surgeons at Northwestern Memorial Hospital ... a new micro-laser, which uses light energy in place ... spine tumors. The technique offers greater precision and ... and patient recovery period following surgery. , Surgeons ...
... 28 Eliaz Babaev, Ph.D., D.Sc., co-founder and CEO ... wound care, presented on the fundamentals of ultrasound assisted ... Technology at the Palais des Congres in Paris, France ... of the foremost authorities on low frequency, therapeutic ultrasound ...
Cached Medicine News:Health News:Former FDA Official Steven Niedelman Joins Crowell & Moring Health Care Group 2Health News:Former FDA Official Steven Niedelman Joins Crowell & Moring Health Care Group 3Health News:Employer Designed Self-Insured Healthcare Conference Offers Unique Perspective 2Health News:Diabetes Keeps Rising Among U.S. Adults 2Health News:Diabetes Keeps Rising Among U.S. Adults 3Health News:Oetzi's last days 2Health News:New laser for neurosurgery allows greater precision and efficiency for removal of complex tumors 2Health News:Arobella Medical CEO Speaks at International Wound Care Conference in Paris 2
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
... ACUSON brand, the new Antares system, ... system that provides highly upgradeable and ... workflow efficiencies, and user-friendly ergonomics. ,The ... upon the advanced workflow and diagnostic ...
Medicine Products: